1 天前 · At Pfizer, we believe that everyone should have the same opportunity to access the latest advances in cancer care, regardless of their background or where they live.

2024年12月20日 · BRAFTOVI in combination with cetuximab and mFOLFOX6 is the first and only combination regimen with targeted therapy approved for use as early as first-line for patients …

2024年11月20日 · Dr. Boshoff, who most recently served as Chief Oncology Officer and Executive Vice President, will succeed Dr. Mikael Dolsten whose departure from Pfizer was …

2024年12月12日 · The first-quarter 2025 cash dividend will be the 345th consecutive quarterly dividend paid by Pfizer. “Our decision to increase our quarterly dividend underscores our …

2024年12月10日 · Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 8:30 a.m. EST on Tuesday, …

2024年12月17日 · Pfizer anticipates full-year 2025 revenues to be in the range of $61.0 to $64.0 billion, which includes the expectation of revenues from our COVID-19 products in 2025 being …

2024年12月12日 · IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine …

In Pfizer Research & Development, you’ll take on the world’s most complex medical challenges from beginning to end. Find your team. Your expertise will be more than just an addition — it …

Join Pfizer Investor Insights. Sign up to receive important updates about Pfizer, how we’re innovating for patients and delivering value for shareholders. Email updates will also provide …

3 天之前 · A Message from Pfizer CEO Albert Bourla: 2024 marks a significant year for Pfizer as we celebrate our 175th anniversary. That’s 175 years of unwavering commitment to advancing …